MET as resistance factor for afatinib therapy and motility driver in gastric cancer cellsKarolin Ebert, Birgit Luber|PLoS ONE|2019Cited by 29
Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell linesKarolin Ebert, Birgit Luber|BMC Cancer|2020Cited by 12